Business
Kelyniam Global Announces Q3 2025 Financial Results
Kelyniam Global Announces Q3 2025 Financial Results.
About this update from Kelyniam Global, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Kelyniam Global Announces Q3 2025 Financial Results\r\n \r\n \r\n\r\n\r\nKelyniam Global Announces Q3 2025 Financial Results\r\n\r\n\r\n\r\n\r\n\r\n\r\n \r\n CANTON, Conn., Nov. 10, 2025 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leader in custom cranial and craniofacial implants, today reported financial results for the third quarter ended September 30, 2025.\r\n \r\n Q3 2025 Financial Highlights (Compared to Q3 2024)\r\n \r\n \r\n Year-to-date revenue of $2,186,491, compared to $2,492,607, a decrease of 12.3%.\r\n Gross profit of $1,695,496, compared to $1,956,714, a decrease of 13.3%, primarily due to the revenue headwinds offset by stable material costs.\r\n Operating loss of $(162,373), compared to operating income of $273,248, reflecting increased investments in sales support and regulatory costs associated with the new Vestakeep® product.\r\n \r\n \"Sales have faced headwinds this year from a slow distributor ramp-up and temporary market share shifts, but through Q3, we're steadily catching up to 2024 levels and building a stronger foundation for sustainable growth,\" said Ross Bjella, CEO of Kelyniam Global. \"The cranial implant sector remains robust, with competitors with overall market projections showing expansion from $1.43 billion in 2024 to over $1.5 billion in 2025. We're capitalizing on this by aggressively adding distributors in untapped markets, where we see tremendous opportunity to capture demand for our rapid-turnaround, custom solutions.\"\r\n \r\n Key Strategic Developments in Q3 2025\r\n \r\n \r\n \r\n FDA Clearance for Vestakeep®: Received 510(k) clearance for this novel resorbable bi-calcium phosphate implant, expanding Kelyniam's portfolio into regenerative applications and addressing unmet needs in craniofacial reconstruction.\r\n \r\n Hospital Approvals Pipeline: The Kelyniam product line is under Value Analytics review approval at six major U.S. hospitals, including two Level 1 trauma centers, potentially adding up to $500,000+ in annual recurring revenue.\r\n \r\n KLYG uplists to OTCID status on OTC Markets Group Platform. This designation underscores Kelyniam's commitment to financial transparency and compliance.\r\n \r\n Kelyniam's complete unaudited financial results for Q3 2025, including detailed segment breakdowns and cash flow statements, are...